Jan Stenvang brings more than 20 years of experience turning scientific innovation into clinical execution. As a biotech founder and previous CSO he has first-hand knowledge in building a biotech company from inception, driving strategy, financing, partnerships, and advancing a pre-clinical lead program into Phase I/II trials. With deep expertise in cancer biology and treatment‑resistant tumors, Jan has led complex R&D and translational drug development efforts. His scientific rigor and execution‑focused leadership position him to guide Kripthonite Therapeutics toward next‑generation therapies for aggressive cancers.

‍

Jan is in charge of driving strategic development of R&D, business strategy, fundraising and partnerships, both academic and with industry.

‍

Kristian Mark Jacobsen, our CSO and co-founder, brings a wealth of knowledge from his time as a postdoc at the Department of Chemistry at Aarhus University. His pioneering research on PH1154, elucidated its potential to combat hypoxic cancer cells, with unparalleled efficacy. Kristian’s dedication to innovation and his relentless pursuit of progress makes him an invaluable asset to our team.

‍

Kristian is responsible for the in vitro and in vivo experiments that demonstrate and benchmark the activity of Kripthonite’s compounds on the road towards clinical use.

CTO, co-inventor: Per is a skilled synthetic chemist with a clear vision for optimization and structural simplification in the development of drug-like molecules. Per has developed all compounds in the Kripthonite portfolio that within a short timeframe and very few iterations advanced from being academically intriguing to highly potent and selective anticancer drug candidates.

‍

Per manages development of Kripthonite’s compound portfolio regarding CMC, ChemInformatics and AI, compound design and medicinal chemistry, formulation and analytical chemistry.

‍

Charlotte is an experienced senior executive with a demonstrated history of establishing and growing a start-up biotech company from idea to a renowned Contract Research Organisation, that is now listed on Nasdaq First North, Stockholm. In Kripthonite Therapeutics, we benefit from her experience with running the day to day operations of a small biotech company.

Søren is a seasoned life science executive with significant experience from operational and strategic leadership positions in global pharma and biotech, e.g. Symphogen, Novo Nordisk, IO Biotech and Macrophage Pharma. He has broad experience across the R&D value chain from lead discovery to clinical development projects. Søren contributes with a strong executive leadership experience from roles in pharma, biotech and non-profit organizations. Additionally, he has significant deal experience from both sell- and buy-side as well as post-transactional collaboration and alliance management.

In parallel to his role as Chairman of the Board, Søren serves as the CEO of Alligator Bioscience AB and as a member of the board of Oblique Therapeutics AB.

‍

Erik Vinther is a commercial leader in pharma and biotech with deep experience guiding products from early development through global launch, such as, early commercial strategy for Rybelsus^® and launch strategy and planning for Wegovy^®. He has held key global, regional, and local roles at Novo Nordisk. With over 14 years of leadership experience, Erik is recognized for building collaborative teams and fostering cross‑functional execution in complex international environments.

Erik is a partner at Marigold Innovation and part of Marigold Maturation Fund that has supported Kripthonite Therapeutics since pre-incorporation.

‍

Chief Scientific Advisor, co-inventor: Thomas is Professor of medicinal chemistry at Aarhus University. He holds a PhD in organic chemistry and a postdoc from Harvard University in cancer biology. Since 2011, he has been an independent researcher with his main interest in bioactive small molecules – often with a focus on anticancer activity. All his projects are driven by his curiosity for compounds with unconventional chemical composition and novel biological mechanisms.

‍

Peter brings experience from more than 20 years across biotech, IP law, strategy, and venture creation. He worked as a researcher, patent attorney, business developer, startup founder, and executive. This experience has taught him where great science needs support and how to design strong, focused companies around academic inventors.

‍

Professor Per thor Straten is an esteemed expert in cancer immunotherapy, leading the Danish-based Center for Cancer Immunotherapy. His extensive research and practical experience make him a valuable advisor in the biotech industry to strategize immunotherapy-related endeavors.

‍

Michael is Professor Emeritus from Aarhus University Hospital with 30+ years of experience in developing and using animal models to characterize and overcome tumor hypoxia.